1) Heidenreich A and Pfister D : Retroperitoneal lymphadenectomy and resection for testicular cancer : an update on best practice. Ther Adv Urol 4 : 187─205, 2012
2) 山田成幸, 齋藤英郎, 荒井陽一, 他 : POOR RISK精巣腫瘍に対する外科的治療─適応とタイミング. 泌外25 : 311─317, 2012
3) Donohue JP, Leviovitch I, Foster RS, et al : Integration of surgery and systemic therapy : results and principles of integration. Semin Urol Oncol 16 : 65─71, 1998
4) O'Carrigan B and Grimison P : Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. Urol Oncol 33 : 343─354, 2015
5) Daneshmand S : Role of surgical resection for refractory germ cell tumors. Urol Oncol 33 : 370─378, 2015
6) Fox EP, Weathers TD, Williams SD, et al : Outcome analysis for patients with persistent nonseminomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncl 11 : 1294─1299, 1993
7) Eggener SE, Carver BS, Leob S, et al : Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer 109 : 528─535, 2007
8) Rick O, Bokemeyer C, Weinknecht S, et al : Residual tumor resecti on after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 22 : 3713─3719, 2004
9) Murphy AM and McKierman JM : Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor. World J Urol 27 : 501─506, 2009
10) McKiernan JM, Motzer RJ, Bajorin DF, et al : Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor : clinical presentation, patterns of recurrence, and outcome. Urology 62 : 732─736, 2003
11) Pedrosa JA, Masterson TA, Rice FR, et al : Reoperative retroperitoneal lymph node dissection formetastatic germ cell tumors : analysis of local recurrence and predictors of survival. J Urol 191 : 1777─1782, 2014
12) Loehrer PJ, Hiu S, Clark S, et al : Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors : a clinicopathologic correlation. J Urol 135 : 1183─1189, 1986
13) Beck SD, Foster RS, Bihrle R, et al : Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23 : 6149─6156, 2005
14) Habuchi T, Kamoto T, Hara I, et al : Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers. Cancer 98 : 1635─1642, 2003
15) Ong TA, Winkler MH, Savage PM, et al : Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers : indications, histopathology and outcome. BJU Int 102 : 198─202, 2008
16) 齋藤 満, 井上高光, 羽渕友則 : 精巣癌 臨床研究 治療 精巣癌の治療研究─化学療法後の腫瘍マーカー陽性例に対する手術療法. 日本臨床68 : 505─509, 2010
17) Beck SD, Foster RS, Bihrle R, et al : Post chemotherapy RPLND in patients with elevated markers : current concepts and clinical outcome. Urol Clin North Am 34 : 219─225, 2007
18) Kamoto T, Satomura S, Yoshiki T, et al : Lectin-reactive alpha-fetoprotein (AFP-L 3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 32 : 472─476, 2002